A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats

Journal of Molecular and Cellular Cardiology

Volumn 40, Issue 5, 2006, Pages 688-695

  Suzuki, Jun Ichi ^a   Ogawa, Masahito ^a   Futamatsu, Hideki ^a   Kosuge, Hisanori ^a   Tanaka, Hiroyuki ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2; Cytokine; Heart Failure; Inflammation; Myocarditis

Indexed keywords

CARDIAC MYOSIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; MELOXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART; HEART RATE; HEART WEIGHT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; MALE; MOLECULAR BIOLOGY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RAT STRAIN; TH1 CELL; TH2 CELL; ANIMAL; DISEASE MODEL; ENZYMOLOGY; LEWIS RAT; METABOLISM; PATHOLOGY; SWINE;

ANIMALIA; SUIDAE;

ANIMALS; AUTOIMMUNE DISEASES; CARDIAC MYOSINS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; MALE; MYOCARDITIS; RATS; RATS, INBRED LEW; SWINE; TH1 CELLS; TH2 CELLS;

EID: 33646102226     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.01.006     Document Type: Article

References (41)

1. Haas G.J. Etiology, evaluation, and management of acute myocarditis. Cardiol. Rev. 9 (2001) 88-95
2. Oakley C.M. Myocarditis JMCC, pericarditis and other pericardial diseases. Heart 84 (2000) 449-454
3. Batra A.S., and Lewis A.B. Acute myocarditis. Curr. Opin. Pediatr. 13 (2001) 234-239
4. Zee-Cheng C.S., Tsai C.C., Palmer D.C., Codd J.E., Pennington D.G., and Williams G.A. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J. Am. Coll. Cardiol. 3 (1984) 63-70
5. Parrillo J.E., Aretz H.T., Palacios I., Fallon J.T., and Block P.C. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure: endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation 69 (1984) 93-101
6. Kiefer W., and Dannhardt G. COX-2 inhibition and the control of pain. Curr. Opin. Investig. Drugs 3 (2002) 1348-1358
7. Stichtenoth D.O., and Frolich J.C. The second generation of COX-2 inhibitors: what advantages do the newest offer?. Drugs 63 (2003) 33-45
8. Bennett A., and Tavares I.A. COX-2 inhibitors compared and contrasted. Expert Opin. Pharmacother. 2 (2001) 1859-1876
9. Koki A., Khan N.K., Woerner B.M., Dannenberg A.J., Olson L., Seibert K., et al. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507 (2002) 177-184
10. Menter D.G. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin. Investig. Drugs 11 (2002) 1749-1764
11. Okamoto T., and Hino O. Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. Int. J. Mol. Med. 6 (2000) 455-457
12. Saito T., and Giaid A. Cyclooxygenase-2 and nuclear factor-kappaB in myocasdium of end stage human heart failure. Congest. Heart Fail. 5 (1999) 222-227
13. Wong S.C., Fukuchi M., Melnyk P., Rodger I., and Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98 (1998) 100-103
14. Kitabayashi H., Isobe M., Watanabe N., Suzuki J., Yazaki Y., and Sekiguchi M. FTY 720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J. Cardiovasc. Pharmacol. 35 (2000) 410-416
15. Yokoseki O., Suzuki J., Kitabayashi H., Watanabe N., Wada Y., Aoki M., et al. cis element decoy against nuclear factor-kappa B attenuates development of experimental autoimmune myocarditis in rats. Circ. Res. 89 (2001) 899-906
16. Futamatsu H., Suzuki J., Kosuge H., Yokoseki O., Kamada M., Ito H., et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc. Res. 59 (2003) 95-104
17. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
18. Litwin S.E., Katz S.E., Morgan J.P., and Douglas P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89 (1994) 345-354
19. Seko Y., Takahashi N., Azuma M., Yagita H., Okumura K., and Yazaki Y. Effects of in vivo administration of anti-B7-1/B7-2 monoclonal anti-bodies on murine acute myocarditis caused by coxsackie virus B3. Circ. Res. 82 (1998) 613-618
20. Suzuki J., Cole S.E., Batirel S., Kosuge H., Shimizu K., Isobe M., et al. Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am. J. Transplant. 3 (2003) 968-976
21. Mason J.W., O'Connell J.B., Herskowitz A., Rose N.R., McManus B.M., Billingham M.E., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333 (1995) 269-275
22. Kodama M., Okura Y., Hirono S., Hanawa H., Ogawa Y., Itoh M., et al. A new scoring system to predict the efficacy of steroid therapy for patients with active myocarditis--a retrospective study. Jpn. Circ. J. 62 (1998) 715-720
23. Brown C.A., and O'Connell J.B. Implications of the Myocarditis Treatment Trial for clinical practice. Curr. Opin. Cardiol. 11 (1996) 332-336
24. Caforio A.L., and McKenna W.J. Recognition and optimum management of myocarditis. Drugs 52 (1996) 515-525
25. Menghini V.V., Savcenko V., Olson L.J., Tazelaar H.D., Dec G.W., Kao A., et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin. Proc. 74 (1999) 1221-1226
26. Frustaci A., Chimenti C., Pieroni M., and Gentiloni N. Giant cell myocarditis responding to immunosuppressive therapy. Chest 117 (2000) 905-907
27. Cooper Jr. L.T. Giant cell myocarditis: diagnosis and treatment. Herz 25 (2000) 291-298
28. Frustaci A., Chimenti C., Calabrese F., Pieroni M., Thiene G., and Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (2003) 857-863
29. Bolli R., Shinmura K., Tang X.L., Kodani E., Xuan Y.T., Guo Y., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc. Res. 55 (2002) 506-519
30. Saito T., Rodger I.W., Hu F., Shennib H., and Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biophys. Res. Commun. 273 (2000) 772-775
31. Chenevard R., Hurlimann D., Bechir M., Enseleit F., Spieker L., Hermann M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107 (2003) 405-409
32. Saito T., Rodger I.W., Shennib H., Hu F., Tayara L., and Giaid A. Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. Can. J. Physiol. Pharmacol. 81 (2003) 114-119
33. Yang X., Ma N., Szabolcs M.J., Zhong J., Athan E., Sciacca R.R., et al. Upregulation of COX-2 during cardiac allograft rejection. Circulation 101 (2000) 430-438
34. Ma N., Szabolcs M.J., Sun J., Albala A., Sciacca R.R., Zhong M., et al. The effect of selective inhibition of cyclooxygenase (COX)-2 on acute cardiac allograft rejection. Transplantation 74 (2002) 1528-1534
35. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., and Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 108 (2001) 585-590
36. Mengle-Gaw L.J., and Schwartz B.D. Cyclooxygenase-2 inhibitors: promise or peril?. Mediators Inflamm. 11 (2002) 275-286
37. Juni P., Dieppe P., and Egger M. Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. Arch. Intern. Med. 162 (2002) 2639-2640
38. Kyrkanides S., Moore A.H., Olschowka J.A., Daeschner J.C., Williams J.P., and Hansen J.T. Kerry O'Banion M. Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. Brain Res. Mol. Brain Res. 104 (2002) 159-169
39. Iniguez M.A., Punzon C., and Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J. Immunol. 163 (1999) 111-119
40. Fernandez P., Guillen M.I., Gomar F., Aller E., Molina P., and Alcaraz M.J. A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis. Biochem. Pharmacol. 68 (2004) 417-421
41. Laouini D., Elkhal A., Yalcindag A., Kawamoto S., Oettgen H., and Geha R.S. COX-2 inhibition enhances the TH2 immune response to epicutaneous sensitization. J. Allergy Clin. Immunol. 116 (2005) 390-396